Pediatric anesthesia & critical care
Role of Angiotensin II as a Vasoactive Agent to Treat Distributive Shock With a Focus on Preliminary Data in Pediatric‐Aged Patients
Authors' conclusion
To date, evidence-based medicine demonstrates an increase in MAP with the ability to wean other vasoactive agents. The current studies do not appear to uniformly and clearly define a survival benefit.
Study context
- Population
- Adult and pediatric patients with distributive (vasoplegic) shock treated with angiotensin II
Main finding
As reported in the abstract
- Adults: Angiotensin II (AT-II) effective for refractory vasodilatory shock when escalating conventional vasoactive agents (norepinephrine ≥ 0.2-0.3 μg/kg/min) have failed, added as third or fourth medication
- Majority of studies: improvement in mean arterial pressure (MAP); limited impact on long-term survival
- Pediatric evidence: 5 case reports and two larger retrospective case series, total of 44 patients; AT-II generally effective in increasing MAP; long-term outcome data not available
- Limited trials of AT-II as primary agent for vasodilatory shock in adults
Original publication
Role of Angiotensin II as a Vasoactive Agent to Treat Distributive Shock With a Focus on Preliminary Data in Pediatric‐Aged Patients. Paediatr Anaesth. Published 9 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →